RTNS 2012

Recent articles

Better tools needed to assess clinical trials

The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.

By Emily Singer
14 May 2012 | 6 min read

Trials and tribulations

Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.

By Emily Singer
11 May 2012 | 3 min read

Compensatory mechanisms

Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.

By Emily Singer
8 May 2012 | 3 min read

Debate over quality of adult-derived stem cells rages on

As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably. 

By Emily Singer
7 May 2012 | 8 min read

Complex case

Multiple levels of complexity make it challenging to develop drugs to treat autism.

By Emily Singer
4 May 2012 | 3 min read

Fast-forward

In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.

By Emily Singer
27 April 2012 | 3 min read

Explore more from The Transmitter

Cell population in brainstem coordinates cough, new study shows

The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.

By Calli McMurray
6 September 2024 | 5 min read
Capitol building
Spectrum Microphone

In updated U.S. autism bill, Congress calls for funding boost, expanded scope

The current Autism CARES Act sunsets in late September.

By Rachel Zamzow
5 September 2024 | 5 min listen
Illustration of ketamine blocking open ion channels in active NMDA receptors, quieting the cells and disrupting downstream signaling involved in depression.

Ketamine targets lateral habenula, setting off cascade of antidepressant effects

The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.

By Olivia Gieger
4 September 2024 | 6 min read